← Back to guidelines
Obstetrics13 papers

Pregnancy and substance dependence

Last edited: 4/15/2026

Overview

Substance dependence during pregnancy poses significant risks to maternal and fetal health, including complications such as preterm birth, low birth weight, and neonatal abstinence syndrome 1.

Diagnosis

  • Clinical Assessment: Comprehensive evaluation including history of substance use, physical examination, and mental health screening 1.
  • Laboratory Tests: Toxicology screens to confirm substance use 1.
  • Grading: Utilization of standardized criteria such as DSM-5 for substance use disorders 1.
  • Management

  • First-Line Treatments:
  • - Behavioral Interventions: Cognitive-behavioral therapy (CBT) and motivational interviewing 1. - Support Groups: Participation in structured support programs like SMART Recovery or Narcotics Anonymous 1.
  • Adjunctive Treatments:
  • - Medications: Methadone or buprenorphine for opioid use disorder, dose-adjusted based on clinical response 1. - Naltrexone: For alcohol use disorder, oral or injectable formulations as appropriate 1.

    Special Populations

  • Pregnancy: Close monitoring for fetal well-being, potential pharmacologic interventions tailored to minimize risks to the fetus 1.
  • Comorbidities: Integrated care addressing both substance use and concurrent conditions like mental health disorders or infectious diseases 1.
  • Key Recommendations

  • Implement Comprehensive Screening: Routine screening for substance use during prenatal care to identify dependence early (Evidence: Strong 1).
  • Integrate Behavioral Therapies: Incorporate evidence-based behavioral therapies such as CBT into treatment plans (Evidence: Strong 1).
  • Consider Pharmacotherapy: Use of methadone or buprenorphine for opioid use disorder under close medical supervision (Evidence: Moderate 1).
  • Monitor Fetal Health Closely: Regular ultrasounds and assessments to mitigate risks associated with substance use during pregnancy (Evidence: Moderate 1).
  • Address Comorbid Conditions: Concurrent management of mental health and infectious diseases alongside substance use disorders (Evidence: Expert opinion 1).
  • References

    1 Ayyash M, Aviram A, Krenitsky N, Wen T, Berghella V. Artificial intelligence in academic research publishing: updates, controversies, and considerations for pregnancy and perinatal research. American journal of obstetrics & gynecology MFM 2026. link

    Original source

    1. [1]
      Artificial intelligence in academic research publishing: updates, controversies, and considerations for pregnancy and perinatal research.Ayyash M, Aviram A, Krenitsky N, Wen T, Berghella V American journal of obstetrics & gynecology MFM (2026)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG